Saturday 14 June 2014

» HT-100 Phase 1b/2a US clinical trial re-started in Duchenne Action Duchenne

» HT-100 Phase 1b/2a US clinical trial re-started in Duchenne Action Duchenne: "DART Therapeutics announced yesterday that it has resumed clinical development for its lead drug candidate, HT-100 (delayed-releasehalofuginone) an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. The company will continue to enroll and dose patients in this ongoing phase 1b/2a clinical study to evaluate the safety and tolerability of increasing doses of HT-100, and explore trends in a range of efficacy endpoints.

Please see the link for the press release for more information:"



'via Blog this'

No comments:

Post a Comment